On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

GlaxoSmithKline (Australia)

InstitutionResearch output, impact & collaborations

GlaxoSmithKline (Australia) is a institution indexed in ScholarIQ from OpenAlex.

What is known about GlaxoSmithKline (Australia)?

ScholarIQrecord summary

GlaxoSmithKline (Australia) is a research organisation in Melbourne, AU. OpenAlex records 221 works and 17,420 citations for it. 55 researchers list it as their most recent affiliation.

How many works does GlaxoSmithKline (Australia) have?

ScholarIQindexed works

GlaxoSmithKline (Australia) has 221 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for GlaxoSmithKline (Australia) →

How many citations does GlaxoSmithKline (Australia) have?

ScholarIQcitation count

GlaxoSmithKline (Australia) has 17,420 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for GlaxoSmithKline (Australia) →

How many researchers are at GlaxoSmithKline (Australia)?

ScholarIQresearcher count

GlaxoSmithKline (Australia) has 55 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at GlaxoSmithKline (Australia)?

ScholarIQavg h-index

GlaxoSmithKline (Australia) has an average h-index of 62 in OpenAlex.

Open the OpenAlex record →

What is the ROR of GlaxoSmithKline (Australia)?

ScholarIQror

The ROR for GlaxoSmithKline (Australia) is on the source record.

Open the ROR →

What is the OpenAlex record for GlaxoSmithKline (Australia)?

ScholarIQopenalex

The OpenAlex for GlaxoSmithKline (Australia) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind GlaxoSmithKline (Australia)?

ScholarIQtop researchers by citations

Michael Millward · Cancer Immunotherapy and Biomarkers

454 works16,268 citations

What are the most-cited papers on GlaxoSmithKline (Australia)?

ScholarIQmost cited works

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber

The Lancet Oncology. 2020528 Citations

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis

Journal of Clinical Oncology. 2012478 CitationsOPEN ACCESS

How much of the research on GlaxoSmithKline (Australia) is open access?

ScholarIQopen access share

50%OPEN ACCESS

Gold

Green

50%

Hybrid

Bronze

Closed

50%